PVI
NGM

Pura Vida Investments’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Pura Vida Investments’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-60,300
Closed -$303K – 183
2022
Q4 		$303K Hold
60,300
– – 0.02% 175
2022
Q3 		$789K Buy
+60,300
New +$913K 0.05% 165

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Pura Vida Investments's NGM Position: Q1 2023 in Review

Pura Vida Investments sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2023, closing a stake of 83,154 shares — an estimated $417K sold.

Pura Vida Investments first reported a position in NGM in Q3 2021 and held it in 4 quarters. The position peaked at $1.77M in Q3 2022. 122 funds tracked by Wall St. Rank hold NGM as of Q1 2023.

  • Pura Vida Investments reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Pura Vida Investments sold 83,154 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $417K.
  • Pura Vida Investments first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 4 quarters.
  • Pura Vida Investments's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1.77M in Q3 2022.
  • 122 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Pura Vida Investments's 13F filing for Q1 2023, filed 15 May 2023.